Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 proof-of-concept placebo-controlled, randomized, parallel group study of AER-901 in patients with either pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH)

Trial Profile

A phase 2 proof-of-concept placebo-controlled, randomized, parallel group study of AER-901 in patients with either pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms uniPHied

Most Recent Events

  • 22 May 2024 Trial design presented at the 120th International Conference of the American Thoracic Society
  • 22 May 2024 Status changed from planning to not yet recruiting as per trial design presented at the 120th International Conference of the American Thoracic Society
  • 20 May 2024 According to an Aerami Therapeutics media release, the trial design of this trial presented at the American Thoracic Society (ATS) 2024 International Conference

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top